[hPTH(1-34) injection].
Uzawa
Toyonobu
T
Scientific Affairs and Sales Promotion Department, Asahi-Kasei Pharma Corporation.
Yamauchi
Hirose
H
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002986:Clinical Trials as Topic; D006801:Humans; D007279:Injections, Subcutaneous; D010006:Osteoblasts / Q000166:cytology / Q000201:enzymology; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D019379:Teriparatide / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology
D019379:Teriparatide; D000469:Alkaline Phosphatase